The merger controversy between Huhons and Huhons Lab has escalated to a shareholder vote at Huhons Global. This situation exemplifies how the merger strategy employed by companies during a period of declining bio investments can become a sensitive issue regarding shareholder value. Attention is now focused on the extraordinary general meeting scheduled for July.
According to industry sources, Huhons Global will hold an extraordinary general meeting on July 3 to gather shareholder opinions on the proposed merger between its listed subsidiary Huhons and the unlisted Huhons Lab. The company is also considering measures to limit voting rights for major shareholders and related parties, indicating that the conflict surrounding the merger is evolving beyond mere stock price concerns to issues of governance and shareholder value.
The merger involves Huhons absorbing Huhons Lab, a subsidiary of Huhons Global. The company describes this as a strategic decision aimed at enhancing its research and development (R&D) competitiveness and securing future growth drivers. Huhons Group has recently denied any connection to succession purposes and clarified that there are currently no plans for major shareholder equity transfers.
Huhons argues that for Huhons Lab, which is responsible for developing biopharmaceuticals, stable funding is necessary to expedite R&D up to the technology transfer stage. The merger is presented as a way to improve both R&D efficiency and financial stability. Additionally, the company cites the need to increase R&D investments in line with government reforms in drug pricing and the trend toward certification for innovative pharmaceutical companies as justification for the merger.
However, market sentiment is lukewarm. There is significant backlash as stakeholders express concerns that the core value of Huhons Lab may shift from Huhons Global, the holding company, to Huhons, the operating company, potentially harming the interests of common shareholders of Huhons Global.
In fact, minority shareholders have voiced their opposition to the merger, claiming it represents a "value transfer favorable to the owner." Shareholder platforms Act and Shareholder Alliance have submitted petitions to the Financial Supervisory Service and the Korea Exchange demanding a thorough review.
As the controversy grows, Huhons Global has decided to directly seek shareholder judgment. The company has accepted a proposal from a special committee to review the appropriateness of the merger and will collect opinions for and against during the extraordinary general meeting on July 3.
The possibility of applying the so-called "3% rule," which limits voting rights for major shareholders and related parties during the appointment and dismissal of audit committee members, is also being considered. This shift indicates that the balance of power in the vote may tilt toward minority shareholders.
An industry insider noted, "If shareholder opposition translates into actual voting outcomes, it could halt the group's merger strategy, making the July extraordinary general meeting a turning point. Conversely, if the company successfully persuades shareholders, it could set a precedent for the internalization of R&D assets in the bio industry."
According to industry sources, Huhons Global will hold an extraordinary general meeting on July 3 to gather shareholder opinions on the proposed merger between its listed subsidiary Huhons and the unlisted Huhons Lab. The company is also considering measures to limit voting rights for major shareholders and related parties, indicating that the conflict surrounding the merger is evolving beyond mere stock price concerns to issues of governance and shareholder value.
The merger involves Huhons absorbing Huhons Lab, a subsidiary of Huhons Global. The company describes this as a strategic decision aimed at enhancing its research and development (R&D) competitiveness and securing future growth drivers. Huhons Group has recently denied any connection to succession purposes and clarified that there are currently no plans for major shareholder equity transfers.
Huhons argues that for Huhons Lab, which is responsible for developing biopharmaceuticals, stable funding is necessary to expedite R&D up to the technology transfer stage. The merger is presented as a way to improve both R&D efficiency and financial stability. Additionally, the company cites the need to increase R&D investments in line with government reforms in drug pricing and the trend toward certification for innovative pharmaceutical companies as justification for the merger.
However, market sentiment is lukewarm. There is significant backlash as stakeholders express concerns that the core value of Huhons Lab may shift from Huhons Global, the holding company, to Huhons, the operating company, potentially harming the interests of common shareholders of Huhons Global.
In fact, minority shareholders have voiced their opposition to the merger, claiming it represents a "value transfer favorable to the owner." Shareholder platforms Act and Shareholder Alliance have submitted petitions to the Financial Supervisory Service and the Korea Exchange demanding a thorough review.
As the controversy grows, Huhons Global has decided to directly seek shareholder judgment. The company has accepted a proposal from a special committee to review the appropriateness of the merger and will collect opinions for and against during the extraordinary general meeting on July 3.
The possibility of applying the so-called "3% rule," which limits voting rights for major shareholders and related parties during the appointment and dismissal of audit committee members, is also being considered. This shift indicates that the balance of power in the vote may tilt toward minority shareholders.
An industry insider noted, "If shareholder opposition translates into actual voting outcomes, it could halt the group's merger strategy, making the July extraordinary general meeting a turning point. Conversely, if the company successfully persuades shareholders, it could set a precedent for the internalization of R&D assets in the bio industry."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.